Luxembourg Institute Of Health
Luxembourg Institute Of Health is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
EORTC 1740: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
EORTC 1612-MG: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
EORTC 2029-LCG: Immunotherapy Consolidation After Radical treatment of de-novo Oligo-metaStatic NSCLC: ICARS
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
Sponsor Universitaetsklinikum Tuebingen AöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (TIGER)
Sponsor Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Luxembourg Institute Of Health?
The 2026-10-09 snapshot links Luxembourg Institute Of Health to 8 distinct CTIS trials. Recorded services include Laboratory services, Biobanking, Clinical monitoring, Regulatory services, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Luxembourg Institute Of Health?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Luxembourg Institute Of Health conducted?
The linked trials record locations in 14 countries, including Spain, Italy, France, Germany, Belgium. These are trial locations, not confirmed office locations or countries where Luxembourg Institute Of Health delivered services.
What can this page tell me about Luxembourg Institute Of Health's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Luxembourg Institute Of Health. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Luxembourg Institute Of Health